JAMA Network
About The Study: This qualitative analysis characterizes the Food and Drug Administration's (FDA's) decision-making with respect to the regulation of mifepristone, with a particular interest in the agency's rationale for establishing, maintaining, or modifying key components of its regulatory approach over time.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
